Although there are limited clinical trial data describing the efficacy of osimertinib combined with MET inhibition in patients with EGFR T790M-mutant NSCLC, outcomes in a real-world setting are useful to inform clinical practice. The gene discussed is MET; the disease is non-small cell lung carcinoma.